Results

Organogenesis Holdings Inc.

06/16/2026 | Press release | Distributed by Public on 06/16/2026 14:33

Proxy Results, Management Change/Compensation (Form 8-K)

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 15, 2026, the holders of our Series A Convertible Preferred Stock voted by written consent to re-elect Garrett Lustig to our board of directors, to serve until the next Annual Meeting of Stockholders and until his successor is elected and qualified.

The information required by this Item 5.02 is incorporated herein by reference to the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission on April 30, 2026.

Item 5.07.

Submission of Matters to a Vote of Security Holders.

We held our 2026 Annual Meeting of Stockholders on June 15, 2026, at which three proposals were submitted to, and approved by, our stockholders. The holders of 129,564,421 shares of our Class A common stock, including 38,470,359 shares of Class A common stock issuable upon conversion of our outstanding Series A Convertible Preferred Stock that are entitled to vote with our Class A common stock on an as-converted basis, were present or represented by proxy at the meeting. The proposals are described in detail in our definitive proxy statement for the 2026 Annual Meeting filed with the Securities and Exchange Commission on April 30, 2026. The final results for the votes for each proposal are set forth below.

At the Annual Meeting, each of Robert Ades, Michael J. Driscoll, Prathyusha Duraibabu, Jon Giacomin, Gary S. Gillheeney, Sr., Michele Korfin, Arthur S. Leibowitz, Glenn H. Nussdorf and Gilberto Quintero was elected our Director, to serve until the next Annual Meeting of Stockholders and until their successors are elected and qualified. The votes cast in the election of the directors were as follows:

Nominee

Votes For Votes Withheld Broker Non-Votes

Robert Ades

85,064,304 235,293 44,264,824

Michael J. Driscoll

76,582,548 8,717,049 44,264,824

Prathyusha Duraibabu

76,767,319 8,532,278 44,264,824

Jon Giacomin

64,825,495 20,474,102 44,264,824

Gary S. Gillheeney, Sr.

76,736,718 8,562,879 44,264,824

Michele Korfin

76,707,741 8,591,856 44,264,824

Arthur S. Leibowitz

76,682,590 8,617,007 44,264,824

Glenn H. Nussdorf

61,049,018 24,250,579 44,264,824

Gilberto Quintero

76,572,688 8,726,909 44,264,824

At the Annual Meeting, our stockholders also approved, on an advisory basis, the compensation paid to our named executive officers. The votes cast on this proposal were as follows:

Proposal

Votes For Votes Against Abstentions Broker
Non-Votes

To approve, on an advisory basis, the compensation paid to our named executive officers.

72,516,011 12,722,258 61,328 44,264,824

2

At the Annual Meeting, our stockholders also approved the proposal to ratify the appointment of RSM US LLP as our independent registered public accounting firm for our fiscal year ending on December 31, 2026. The votes cast on this proposal were as follows:

Proposal

Votes For Votes Against Abstentions Broker
Non-Votes

To ratify the appointment of RSM US LLP as our independent registered public accounting firm for fiscal year 2026.

128,421,160 856,933 286,328 0

3

Organogenesis Holdings Inc. published this content on June 16, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 16, 2026 at 20:33 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]